trivalent GSC-targeting DC vaccine / Oslo University Hospital - LARVOL DELTA

DEN-STEM: Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: Oslo University Hospital | Active, not recruiting ➔ Recruiting | Trial completion date: May 2025 ➔ May 2026 | Trial primary completion date: May 2023 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • MGMT